Updates : In-vitro Pre-clinical trials ✅
About Us:
Mirai Therapeutics, an innovative early-stage company, is at the forefront of addressing the critical challenge in the field of nanomedicine - thromboinflammation. This detrimental immune response, characterized by inflammation and blood clot formation, leading to the rejection of the nanovehicles introduced into the bloodstream.
Our main product is a novel venom-derived polypeptide that reduces thromboinflammation. This breakthrough allows nanovehicles to deliver their therapeutic payloads without triggering thromboinflammation.
We also offer a service that measures thromboinflammation levels. This service provides valuable information for researchers, drug developers, enabling them to use nanovehicles safely and effectively in medical settings.
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://mirai.framer.ai/
Mirai Therapeutics Questions
Mirai Therapeutics's website is https://mirai.framer.ai/
Mirai Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mirai-therapeutics
Mirai Therapeutics's industry is
Biotechnology Research
Mirai Therapeutics's top competitors are
Orbital Therapeutics,
Nvelop Therapeutics,
Sail Biomedicines,
Mirai Bio,
Thymmune Therapeutics,
Mirai Bionexus,
Tessera Therapeutics,
City Therapeutics,
Flagship Pioneering,
Nanovation Therapeutics™.
Mirai Therapeutics's categories are Biotechnology Research
